Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients with Sickle Cell Disease Who Are At Increased Risk for Primary Stroke

Next Previous
Trial Profile

A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients with Sickle Cell Disease Who Are At Increased Risk for Primary Stroke

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etavopivat (Primary) ; Hydroxycarbamide
  • Indications Sickle cell anaemia
  • Focus Pharmacodynamics
  • Acronyms HIBISCUS 3
  • Sponsors FORMA Therapeutics

Most Recent Events

  • 10 Sep 2026 Planned End Date changed from 20 Sep 2027 to 28 Jun 2028.
  • 10 Sep 2026 Planned primary completion date changed from 20 Sep 2027 to 20 Aug 2027.
  • 16 Jul 2025 Planned number of patients changed from 46 to 27.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top